Publications by authors named "J L Pickett"

A centralized safety function can support multiple clinical trials and provide efficient, standardized processes for the management of serious adverse events. From 2017 to 2022, the centralized safety desk used pharmacovigilance software compliant with FDA regulations, including 21 CFR Part 11. This software assisted with processing safety cases for regulated clinical trials, including allowing capture of event data, and provided process flow management, documentation storage, and transmission of safety reports to FDA.

View Article and Find Full Text PDF

Background: Sexual and gender minority (SGM) adolescents in the United States are disproportionately affected by HIV. Pre-exposure prophylaxis (PrEP) is a highly effective biomedical HIV prevention method, but its awareness and uptake among SGM adolescents are low. There are no adolescent-centered PrEP social marketing campaigns in the United States that have the potential to increase awareness and interest in PrEP.

View Article and Find Full Text PDF

The vascular cell adhesion molecule-1 (VCAM-1) plays an important role in inflammation, where it facilitates the recruitment of leukocytes to the inflamed area via leukocytes' VLA-4 and endothelial cells' VCAM-1 interaction. VCAM-1 expression is also upregulated in certain cancers. VCAM-1 has seven Ig-like domains, with domains 1 and 4 shown to be critical for VLA-4 binding.

View Article and Find Full Text PDF

Atherosclerosis is a chronic inflammatory vascular disorder driven by factors such as endothelial dysfunction, hypertension, hyperlipidemia, and arterial calcification, and is considered a leading global cause of death. Existing atherosclerosis models have limitations due to the absence of an appropriate hemodynamic microenvironment and interspecies differences . Here, we develop a simple but robust microfluidic intimal-lumen model of early atherosclerosis using interconnected dual channels for studying monocyte transmigration and foam cell formation at an arterial shear rate.

View Article and Find Full Text PDF
Article Synopsis
  • Respiratory syncytial virus (RSV) commonly causes respiratory illnesses, especially severe in adults over 60 or those with chronic conditions; a study examined the cost-effectiveness of the RSVPreF3 vaccine for this age group in the US.* -
  • A multi-cohort Markov model compared outcomes of not vaccinating versus a one-time vaccination, estimating that vaccinating approximately 52.7 million older adults would save nearly 244,424 quality-adjusted life years (QALYs) at a societal cost of about $4.5 billion over five years.* -
  • The analysis indicated that the adjuvanted RSVPreF3 vaccine is cost-effective, with an incremental cost-effectiveness ratio (
View Article and Find Full Text PDF